Novartis Scores Back-To-Back Jury Wins in Bone Cancer Drug Labeling Suits
Novartis and Hollingsworth, its national counsel in litigation over the cancer drug Zometa, got a double dose of good news in the past week with federal juries in Kentucky and St. Louis throwing out failure-to-warn claims by plaintiffs who blamed the company for their jaw disease.
This premium content is reserved for American Lawyer subscribers.
Continue reading by getting started with a subscription.
Already a subscriber? Log in now